Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

RenovoRx, Inc.

RNXT · Nasdaq · CIK 0001574094 · Healthcare · Biotechnology

INSIDER SIGNAL

35.6 / 100

1 buyers · 1 purchase transaction lines · $19.8K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+2.8 / 25
Role+15.0 / 20
Recency+0.8 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Chief Financial Officer

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
VOLL MARKChief Financial Officer
●○
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: VOLL MARK · $19.8K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-19–2026-05-19

Roles in the peak window: Chief Financial Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

35.6 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 35.7
  2. 35.7
  3. 35.7
  4. 35.6
  5. 35.6

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

13Purchases
0Sales
3Other Form 4 lines
15SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER1 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-27.7%
3M
+40.2%
6M
+29.9%
12M
+5.8%

Volatility & liquidity

Volatility
81.8%
Beta
—
Avg daily value
USD 1.0M

Valuation

Market cap
USD 57.8M
P/E
—

Fundamentals

Profit margin
-994.5%
ROE
-206.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-07 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
946,982
Previous report
673,558
Avg daily volume
597,351
Days to cover
1.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-19VOLL MARKPurchase (P)Common Stock25,000USD 0.79USD 19,750SEC filing ↗
2026-03-20VOLL MARKPurchase (P)Common Stock97,200USD —USD —SEC filing ↗
2026-03-20Marton LaurencePurchase (P)Common Stock9,720USD —USD —SEC filing ↗
2026-03-20Bagai ShaunPurchase (P)Common Stock24,300USD —USD —SEC filing ↗
2026-01-21Agah RamtinPurchase (P)Common Stock10,000USD 1.00USD 10,000SEC filing ↗
2025-12-31Agah RamtinPurchase (P)Common Stock9,795USD 0.86USD 8,424SEC filing ↗
2025-12-30Agah RamtinPurchase (P)Common Stock205USD 0.83USD 170SEC filing ↗
2025-12-18Bagai ShaunPurchase (P)Common Stock5,000USD 0.90USD 4,500SEC filing ↗
2025-12-17Bagai ShaunPurchase (P)Common Stock5,000USD 0.85USD 4,250SEC filing ↗
2025-12-16Agah RamtinPurchase (P)Common Stock12,000USD 0.85USD 10,200SEC filing ↗
2025-12-05Agah RamtinPurchase (P)Common Stock10,000USD 0.96USD 9,600SEC filing ↗
2025-11-24Agah RamtinPurchase (P)Common Stock12,000USD 0.80USD 9,600SEC filing ↗
2025-11-21Agah RamtinPurchase (P)Common Stock10,000USD 0.80USD 8,000SEC filing ↗
2025-08-25Bagai ShaunPurchase (P)Common Stock5,000USD 0.91USD 4,550SEC filing ↗
2025-08-22Bagai ShaunPurchase (P)Common Stock5,000USD 0.95USD 4,750SEC filing ↗

Form 4 evidence

16 transaction lines in the latest 365-day window; 44 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-10VOLL MARKAward / grant (A)Common Stock80,000USD 0.00USD 0SEC filing ↗
2026-05-19VOLL MARKPurchase (P)Common Stock25,000USD 0.79USD 19,750SEC filing ↗
2026-04-03VOLL MARKAward / grant (A)Common Stock80,000USD 0.00USD 0SEC filing ↗
Show recent Form 4 evidence (16 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-09-10VOLL MARKAward / grant (A)Common Stock80,000USD 0.00USD 0SEC filing ↗
2026-05-19VOLL MARKPurchase (P)Common Stock25,000USD 0.79USD 19,750SEC filing ↗
2026-04-03VOLL MARKAward / grant (A)Common Stock80,000USD 0.00USD 0SEC filing ↗
2026-03-25VOLL MARKAward / grant (A)Common Stock12,380USD 0.00USD 0SEC filing ↗
2026-03-20VOLL MARKPurchase (P)Common Stock97,200USD —USD —SEC filing ↗
2026-03-20Marton LaurencePurchase (P)Common Stock9,720USD —USD —SEC filing ↗
2026-03-20Bagai ShaunPurchase (P)Common Stock24,300USD —USD —SEC filing ↗
2026-01-21Agah RamtinPurchase (P)Common Stock10,000USD 1.00USD 10,000SEC filing ↗
2025-12-31Agah RamtinPurchase (P)Common Stock9,795USD 0.86USD 8,424SEC filing ↗
2025-12-30Agah RamtinPurchase (P)Common Stock205USD 0.83USD 170SEC filing ↗
2025-12-18Bagai ShaunPurchase (P)Common Stock5,000USD 0.90USD 4,500SEC filing ↗
2025-12-17Bagai ShaunPurchase (P)Common Stock5,000USD 0.85USD 4,250SEC filing ↗
2025-12-16Agah RamtinPurchase (P)Common Stock12,000USD 0.85USD 10,200SEC filing ↗
2025-12-05Agah RamtinPurchase (P)Common Stock10,000USD 0.96USD 9,600SEC filing ↗
2025-11-24Agah RamtinPurchase (P)Common Stock12,000USD 0.80USD 9,600SEC filing ↗
2025-11-21Agah RamtinPurchase (P)Common Stock10,000USD 0.80USD 8,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerRNXT
CIK0001574094
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC3841 Surgical & Medical Instruments & Apparatus
ExchangeNasdaq

Data coverage

Local Form 4 history44 transaction lines from 2021-08-30 to 2026-09-10
36 P purchase lines · 0 S sale lines · 8 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.